Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$168.98−1.28 (-0.75%)
Close on Nov 18, 2026Market cap $209.59BP/E –Yield 1.87%
Gilead Sciences r&d expenses
Research and development expenses are spending on new products and technology.
Gilead Sciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $6.33B, up 8.0% year over year. For fiscal 2025 it was $5.80B, down 1.8% from the year before. Over ten years it grew 6.8% a year on average. The highest annual figure on record is $5.91B in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.80B | -1.8% |
| FY2024 | Dec 31, 2024 | $5.91B | +3.3% |
| FY2023 | Dec 31, 2023 | $5.72B | +14.9% |
| FY2022 | Dec 31, 2022 | $4.98B | +8.2% |
| FY2021 | Dec 31, 2021 | $4.60B | -6.6% |
| FY2020 | Dec 31, 2020 | $4.93B | +21.5% |
| FY2019 | Dec 31, 2019 | $4.06B | +3.4% |
| FY2018 | Dec 31, 2018 | $3.92B | +5.0% |
| FY2017 | Dec 31, 2017 | $3.73B | -26.8% |
| FY2016 | Dec 31, 2016 | $5.10B | +69.1% |
| FY2015 | Dec 31, 2015 | $3.01B | +5.6% |
| FY2014 | Dec 31, 2014 | $2.85B | +34.6% |
| FY2013 | Dec 31, 2013 | $2.12B | +20.5% |
| FY2012 | Dec 31, 2012 | $1.76B | +43.2% |
| FY2011 | Dec 31, 2011 | $1.23B | +14.6% |
| FY2010 | Dec 31, 2010 | $1.07B | +14.2% |
| FY2009 | Dec 31, 2009 | $939.92M | +30.2% |
| FY2008 | Dec 31, 2008 | $721.77M | +22.1% |
| FY2007 | Dec 31, 2007 | $591.03M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.61B | +19.5% |
| Q2 FY2026 | Jun 30, 2026 | $1.76B | +18.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.37B | -0.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.58B | -3.5% |
| Q3 FY2025 | Sep 30, 2025 | $1.35B | -3.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.49B | +10.4% |
| Q1 FY2025 | Mar 31, 2025 | $1.38B | -9.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.64B | +16.5% |
| Q3 FY2024 | Sep 30, 2024 | $1.40B | -4.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.35B | -4.0% |
| Q1 FY2024 | Mar 31, 2024 | $1.52B | +5.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.41B | -9.0% |
| Q3 FY2023 | Sep 30, 2023 | $1.46B | +26.8% |
| Q2 FY2023 | Jun 30, 2023 | $1.41B | +27.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.45B | +22.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.55B | +14.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.15B | +4.4% |
| Q2 FY2022 | Jun 30, 2022 | $1.10B | +0.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.18B | +11.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.36B | -7.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.10B | -4.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.09B | -15.9% |
| Q1 FY2021 | Mar 31, 2021 | $1.06B | +5.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.47B | +33.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.16B | +12.4% |
| Q2 FY2020 | Jun 30, 2020 | $1.30B | +30.6% |
| Q1 FY2020 | Mar 31, 2020 | $1.00B | -5.0% |
| Q4 FY2019 | Dec 31, 2019 | $1.10B | +29.0% |
| Q3 FY2019 | Sep 30, 2019 | $1.03B | +9.7% |
| Q2 FY2019 | Jun 30, 2019 | $995.00M | -16.5% |
| Q1 FY2019 | Mar 31, 2019 | $1.06B | +12.8% |
| Q4 FY2018 | Dec 31, 2018 | $852.00M | -25.9% |
| Q3 FY2018 | Sep 30, 2018 | $939.00M | +19.0% |
| Q2 FY2018 | Jun 30, 2018 | $1.19B | +38.0% |
| Q1 FY2018 | Mar 31, 2018 | $937.00M | +0.6% |
| Q4 FY2017 | Dec 31, 2017 | $1.15B | -4.8% |
| Q3 FY2017 | Sep 30, 2017 | $789.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $864.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $931.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.21B | – |
See a number that looks wrong?